Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer

被引:29
作者
Corsello, SM
Rota, CA
Putignano, P
Della Casa, S
Barnabei, A
Migneco, MG
Vangeli, V
Barini, A
Mandalà, M
Barone, C
Barbarino, A
机构
[1] Catholic Univ, Sch Med, Inst Endocrinol, Rome, Italy
[2] Catholic Univ, Sch Med, Inst Biochem, Rome, Italy
[3] Catholic Univ, Sch Med, Inst Internal Med, Rome, Italy
关键词
D O I
10.1530/eje.0.1390309
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Tamoxifen, an estrogen antagonist, is usually employed in the treatment of breast cancer. Its mechanism of action is not well known because an antiproliferative effect of the drug has been shown also in estrogen receptor negative tumors, most likely mediated by the inhibition of local growth factors and particularly IGF-I. However, the action of tamoxifen on the GH-IGF-I axis is still open to investigation, We have investigated the influence of acute and chronic treatment with tamoxifen on GH response to GHRH and IGF-I serum levels in six postmenopausal women with metastatic breast cancer. A GHRH test (50 mu g i.v. at time 0, GH determinations at 0, 15, 30, 60, 90 and 120 min) was performed (a) basally, (b) 3 h after 40 mg oral administration of tamoxifen and (c) after 8 weeks of 20 mg twice a day oral tamoxifen treatment. IGF-I was measured basally and after chronic tamoxifen therapy. No significant modifications in GH response to GHRH were observed after acute or chronic treatment with tamoxifen vs the basal test. On the contrary, chronic tamoxifen treatment induced a significant decrease in serum IGF-I levels. Basal pretreatment levels of 123 +/- 18 mu g/l were suppressed to 65 +/- 11 mu g/l (mean suppression 47%, P < 0.001). These preliminary data confirm the inhibitory effect of tamoxifen on IGF-I production but seem to exclude the possibility that this effect may be due to an inhibition of GH secretion.
引用
收藏
页码:309 / 313
页数:5
相关论文
共 17 条
[1]
ABE O, 1992, LANCET, V339, P71
[2]
ARTEAGA CL, 1989, CANCER RES, V49, P6237
[3]
GROWTH-HORMONE AND PROLACTIN SECRETION AFTER GROWTH HORMONE-RELEASING HORMONE ADMINISTRATION, IN ANOREXIA-NERVOSA PATIENTS, NORMAL CONTROLS AND TAMOXIFEN-PRETREATED VOLUNTEERS [J].
CASANUEVA, FF ;
BORRAS, CG ;
BURGUERA, B ;
LIMA, L ;
MURUAIS, C ;
TRESGUERRES, JAF ;
DEVESA, J .
CLINICAL ENDOCRINOLOGY, 1987, 27 (05) :517-523
[4]
COLLETTI RB, 1989, CANCER RES, V49, P1882
[5]
*EARL BREAST CANC, 1992, LANCET, V339, P1
[6]
ESTROGENIC EFFECTS OF ADJUVANT TAMOXIFEN IN POSTMENOPAUSAL BREAST-CANCER [J].
FORNANDER, T ;
RUTQVIST, LE ;
WILKING, N ;
CARLSTROM, K ;
VONSCHOULTZ, B .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) :497-500
[7]
GROWTH-HORMONE AND SOMATOMEDIN-C DURING POST-MENOPAUSAL REPLACEMENT THERAPY WITH ESTROGEN ALONE AND IN COMBINATION WITH AN ANTIOESTROGEN [J].
FROHLANDER, N ;
VONSCHOULTZ, B .
MATURITAS, 1988, 9 (04) :297-302
[8]
FURLANETTO RW, 1984, CANCER RES, V44, P2122
[9]
PLASMA HORMONES IN PATIENTS WITH ADVANCED BREAST-CANCER TREATED WITH TAMOXIFEN [J].
GOLDER, MP ;
PHILLIPS, MEA ;
FAHMY, DR ;
PREECE, PE ;
JONES, V ;
HENK, JM ;
GRIFFITHS, K .
EUROPEAN JOURNAL OF CANCER, 1976, 12 (09) :719-723
[10]
INFLUENCE OF TAMOXIFEN, AMINOGLUTETHIMIDE AND GOSERELIN ON HUMAN PLASMA IGF-I LEVELS IN BREAST-CANCER PATIENTS [J].
LIEN, EA ;
JOHANNESSEN, DC ;
AAKVAAG, A ;
LONNING, PE .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 41 (3-8) :541-543